Surmodics, Inc. (NASDAQ:SRDX – Free Report) – Investment analysts at Zacks Research raised their FY2025 earnings estimates for shares of Surmodics in a report released on Tuesday, January 28th. Zacks Research analyst D. Dey now anticipates that the company will earn $0.17 per share for the year, up from their prior forecast of $0.16. The consensus estimate for Surmodics’ current full-year earnings is $0.19 per share. Zacks Research also issued estimates for Surmodics’ Q4 2026 earnings at $0.27 EPS, FY2026 earnings at $0.83 EPS and FY2027 earnings at $0.88 EPS.
Surmodics (NASDAQ:SRDX – Get Free Report) last posted its earnings results on Thursday, February 6th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.04. Surmodics had a negative net margin of 9.15% and a negative return on equity of 3.79%.
Get Our Latest Stock Report on SRDX
Surmodics Trading Down 0.8 %
SRDX opened at $35.48 on Thursday. The firm has a market capitalization of $507.15 million, a price-to-earnings ratio of -43.80 and a beta of 1.21. Surmodics has a one year low of $25.17 and a one year high of $42.44. The business has a 50 day simple moving average of $38.81 and a two-hundred day simple moving average of $39.21. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.96 and a quick ratio of 3.22.
Insider Activity
In related news, CFO Timothy J. Arens sold 7,009 shares of the stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $39.44, for a total value of $276,434.96. Following the completion of the transaction, the chief financial officer now directly owns 70,350 shares in the company, valued at $2,774,604. This trade represents a 9.06 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 8.90% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Surmodics
Several hedge funds have recently bought and sold shares of the business. Rhumbline Advisers increased its stake in shares of Surmodics by 4.4% during the fourth quarter. Rhumbline Advisers now owns 20,250 shares of the company’s stock valued at $802,000 after purchasing an additional 861 shares in the last quarter. R Squared Ltd purchased a new stake in shares of Surmodics in the 4th quarter worth approximately $55,000. SG Americas Securities LLC grew its stake in shares of Surmodics by 22.1% in the 4th quarter. SG Americas Securities LLC now owns 6,940 shares of the company’s stock worth $275,000 after buying an additional 1,255 shares during the last quarter. Modus Advisors LLC bought a new position in Surmodics during the 4th quarter valued at approximately $40,000. Finally, JPMorgan Chase & Co. raised its stake in Surmodics by 192.7% during the third quarter. JPMorgan Chase & Co. now owns 42,470 shares of the company’s stock valued at $1,647,000 after buying an additional 27,960 shares during the last quarter. Institutional investors own 96.63% of the company’s stock.
About Surmodics
Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).
Featured Stories
- Five stocks we like better than Surmodics
- With Risk Tolerance, One Size Does Not Fit All
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- How to Choose Top Rated Stocks
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Surmodics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics and related companies with MarketBeat.com's FREE daily email newsletter.